{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:16Z","timestamp":1784408836868,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02377-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:04:38Z","timestamp":1751360678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature"],"prefix":"10.1007","volume":"16","author":[{"given":"Elie S.","family":"Bterrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois G.","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"5","key":"2377_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJMoa1505181","volume":"374","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Hodi FS, Brahmer JR. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2015;374(5):483\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1505181.","journal-title":"N Engl J Med"},{"issue":"22","key":"2377_CR2","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.2016.68.7593","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R. Assessment of immune-related adverse events associated with immune checkpoint inhibitors. J Clin Oncol. 2016;34(22):2548\u201355. https:\/\/doi.org\/10.1200\/JCO.2016.68.7593.","journal-title":"J Clin Oncol"},{"key":"2377_CR3","volume-title":"Bullous pemphigoid","author":"P Joly","year":"2016","unstructured":"Joly P, Maho-Vaillant M, Roujeau JC. Bullous pemphigoid. Cham: Springer; 2016."},{"issue":"16","key":"2377_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1904245","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab plus ipilimumab in melanoma with brain metastases. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1904245.","journal-title":"N Engl J Med"},{"issue":"21","key":"2377_CR5","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/cancers14215451","volume":"14","author":"W Shalata","year":"2022","unstructured":"Shalata W, Weissmann S, Gabay SI, Sheva K, Saleh OA, Jama AA, Yakobson A, Rouvinov K. A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors. Cancers. 2022;14(21):5451. https:\/\/doi.org\/10.3390\/cancers14215451.","journal-title":"Cancers"},{"key":"2377_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fonc.2017.00355","volume":"7","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Yang F, Zheng Y. Anti-PD-1 antibodies and their role in cancer treatment. Front Oncol. 2017;7:355. https:\/\/doi.org\/10.3389\/fonc.2017.00355.","journal-title":"Front Oncol"},{"issue":"7","key":"2377_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, Zhang Y, Zhou X, Wang Z, Wang Y, Shi Y, Bai H, Liu N, Yang X, Cui X, Cao Y, Liu Q, Song J, Li Y, Li K. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immun. 2018;67(7):1079\u201390. https:\/\/doi.org\/10.1007\/s00262-018-2160-x.","journal-title":"Cancer Immunol Immun"},{"issue":"4","key":"2377_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nri3843","volume":"15","author":"CA Klebanoff","year":"2015","unstructured":"Klebanoff CA, Gattinoni L. Memory T cell recall in cancer immunotherapy. Nat Rev Immunol. 2015;15(4):345\u201359. https:\/\/doi.org\/10.1038\/nri3843.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2377_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3245","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3245.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2377_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2340\/00015555-2722","volume":"97","author":"P Joly","year":"2017","unstructured":"Joly P, Bernard P, Prost-Squarcioni C. Bullous pemphigoid: current knowledge. Acta Derm Venereol. 2017;97(6):767\u201377. https:\/\/doi.org\/10.2340\/00015555-2722.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2377_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","volume":"138","author":"L Lin","year":"2017","unstructured":"Lin L, Hwang B, Culton DA, Li N, Burette S, Koller BH, Messingham KA, Fairley JA, Lee JJ, Hall RP, An L, Diaz LA, Liu Z. Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Investig Dermatol. 2017;138(5):1032\u201343. https:\/\/doi.org\/10.1016\/j.jid.2017.11.031.","journal-title":"J Investig Dermatol"},{"key":"2377_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102335","volume":"106","author":"M Dresow","year":"2020","unstructured":"Dresow M, Schmidt E, Bruckner-Tuderman L. Eosinophils and cytokines in bullous pemphigoid. J Autoimmun. 2020;106: 102335. https:\/\/doi.org\/10.1016\/j.jaut.2020.102335.","journal-title":"J Autoimmun"},{"issue":"2","key":"2377_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jdermsci.2016.08.003","volume":"83","author":"YS Bae","year":"2016","unstructured":"Bae YS, Kim HJ, Cho YT, Kim MB. Interleukin-4 and interleukin-5 in the pathogenesis of bullous pemphigoid. J Dermatol Sci. 2016;83(2):115\u201322. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.08.003.","journal-title":"J Dermatol Sci"},{"key":"2377_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2018.04.013","volume":"192","author":"J Yamagami","year":"2018","unstructured":"Yamagami J, Asano Y. IgG subclasses and complement activation in autoimmune blistering diseases. Clin Immunol. 2018;192:21\u20137. https:\/\/doi.org\/10.1016\/j.clim.2018.04.013.","journal-title":"Clin Immunol"},{"key":"2377_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.coi.2016.10.009","volume":"42","author":"C Sitaru","year":"2016","unstructured":"Sitaru C, Zillikens D. Bullous pemphigoid. Curr Opin Immunol. 2016;42:70\u20137. https:\/\/doi.org\/10.1016\/j.coi.2016.10.009.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2377_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jdermsci.2022.05.007","volume":"106","author":"S Liu","year":"2022","unstructured":"Liu S, Zhao L, Zhang X, Liu H. The impact of immune checkpoint inhibitors on the development of bullous pemphigoid: a systematic review and meta-analysis. J Dermatol Sci. 2022;106(3):117\u201324. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.05.007.","journal-title":"J Dermatol Sci"},{"issue":"6382","key":"2377_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"2377_CR18","unstructured":"Merck & Co. (2021). Pembrolizumab (Keytruda) prescribing information. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"issue":"2","key":"2377_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/CJI.0000000000000468","volume":"44","author":"Y Feng","year":"2021","unstructured":"Feng Y, Zhang X, Yang L. Anti-CTLA-4 and its clinical implications in cancer immunotherapy. J Immunother. 2021;44(2):56\u201366. https:\/\/doi.org\/10.1097\/CJI.0000000000000468.","journal-title":"J Immunother"},{"issue":"5","key":"2377_CR20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1078-0432.CCR-20-3122","volume":"27","author":"AM Goodman","year":"2021","unstructured":"Goodman AM, Sokol ES, Moreira A. The role of ipilimumab in cancer treatment: a review of its mechanism and efficacy. Clin Cancer Res. 2021;27(5):1207\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3122.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2377_CR21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1506820","volume":"373","author":"JR Brahmer","year":"2015","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Smith DC. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2015;373(20):1920\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1506820.","journal-title":"N Engl J Med"},{"issue":"26","key":"2377_CR22","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1616338","volume":"366","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Hodi FS, Brahmer JR. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2016;366(26):2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1616338.","journal-title":"N Engl J Med"},{"issue":"3","key":"2377_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/09546634.2020.1845501","volume":"32","author":"H Wang","year":"2021","unstructured":"Wang H, Liu S, Lu Z. Autoimmune blistering disorders: a comprehensive review. J Dermatol Treat. 2021;32(3):250\u20138. https:\/\/doi.org\/10.1080\/09546634.2020.1845501.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"2377_CR24","first-page":"301","volume":"78","author":"P Joly","year":"2018","unstructured":"Joly P, Amoura Z, Boulard M. Management of bullous pemphigoid: a comprehensive review. J Am Acad Dermatol. 2018;78(2):301\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2377_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/09546634.2016.1217747","volume":"28","author":"E Schmidt","year":"2017","unstructured":"Schmidt E, Zillikens D, Rzany B. Bullous pemphigoid: a review and treatment recommendations. J Dermatol Treat. 2017;28(2):175\u201384. https:\/\/doi.org\/10.1080\/09546634.2016.1217747.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"2377_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjd.14335","volume":"175","author":"R Sarkany","year":"2016","unstructured":"Sarkany R, Perkins W, Evans M. Use of systemic immunosuppressants in bullous pemphigoid: a review. Br J Dermatol. 2016;175(1):123\u201330. https:\/\/doi.org\/10.1111\/bjd.14335.","journal-title":"Br J Dermatol"},{"key":"2377_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108848","volume":"235","author":"J Labrador","year":"2021","unstructured":"Labrador J, Gonzalez F, Rodriguez M. Immune checkpoint inhibitor-induced bullous pemphigoid: current insights and management strategies. Clin Immunol. 2021;235: 108848. https:\/\/doi.org\/10.1016\/j.clim.2021.108848.","journal-title":"Clin Immunol"},{"issue":"2","key":"2377_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdermsci.2021.11.003","volume":"40","author":"M Fazio","year":"2022","unstructured":"Fazio M, Volpe A, Marasca C. Bullous pemphigoid induced by immune checkpoint inhibitors: a review of cases and management strategies. J Clin Dermatol. 2022;40(2):123\u201331. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.11.003.","journal-title":"J Clin Dermatol"},{"issue":"7","key":"2377_CR29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00262-022-03274-0","volume":"71","author":"S Patel","year":"2022","unstructured":"Patel S, Smith D, Greenberg M. Combined approach to immune checkpoint inhibitor-induced bullous pemphigoid: a case series and literature review. Cancer Immunol Immunother. 2022;71(7):1561\u201370. https:\/\/doi.org\/10.1007\/s00262-022-03274-0.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2377_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jaad.2016.12.014","volume":"76","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Schindler K, Lacouture ME, et al. Immune-related dermatologic adverse events associated with immune checkpoint blockade: a systematic review. J Am Acad Dermatol. 2017;76(4):779\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.014.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2377_CR31","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13904","volume":"57","author":"AT Lopez","year":"2018","unstructured":"Lopez AT, Khanna T, Antonov N, Kim J. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57(6):664\u20139. https:\/\/doi.org\/10.1111\/ijd.13904.","journal-title":"Int J Dermatol"},{"issue":"2","key":"2377_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamadermatol.2017.4566","volume":"154","author":"J Siegel","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M. Bullous pemphigoid following anti-PD-1 therapy. JAMA Dermatol. 2018;154(2):271\u20133. https:\/\/doi.org\/10.1001\/jamadermatol.2017.4566.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2377_CR33","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1111\/jdv.16887","volume":"34","author":"NN Uppal","year":"2020","unstructured":"Uppal NN, Lipner SR. JAK inhibitors for refractory bullous pemphigoid: a novel therapeutic approach. J Eur Acad Dermatol Venereol. 2020;34(12):e821\u20132. https:\/\/doi.org\/10.1111\/jdv.16887.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2377_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001.","journal-title":"Cancer Treat Rev"},{"key":"2377_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731774","author":"X Zhang","year":"2021","unstructured":"Zhang X, Sui D, Wang D, Zhang L, Wang R. Case report: a rare case of pembrolizumab induced bullous pemphigoid. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.731774.","journal-title":"Front Immunol"},{"key":"2377_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21770","author":"T Chatterjee","year":"2022","unstructured":"Chatterjee T, Rashid TF, Syed SB, Roy M. Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.21770.","journal-title":"Cureus"},{"issue":"5","key":"2377_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jdcr.2020.03.003","volume":"6","author":"C Qiu","year":"2020","unstructured":"Qiu C, Shevchenko A, Hsu S. Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis. JAAD Case Rep. 2020;6(5):400\u20132. https:\/\/doi.org\/10.1016\/j.jdcr.2020.03.003.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"2377_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jdcr.2019.02.008","volume":"5","author":"CW Sun","year":"2019","unstructured":"Sun CW, Grossman SK, Aphale A, Hsu S. Pembrolizumab-induced bullous pemphigoid. JAAD Case Rep. 2019;5(4):362\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2019.02.008.","journal-title":"JAAD Case Rep"},{"key":"2377_CR39","doi-asserted-by":"publisher","DOI":"10.5603\/fd.100000","author":"R Olech","year":"2024","unstructured":"Olech R, Rychlik-Grabowska M, Ma\u0144dziuk S. Refractory bullous pemphigoid during treatment with pembrolizumab in the first-line treatment of advanced non-small cell lung cancer. Forum Dermatol. 2024. https:\/\/doi.org\/10.5603\/fd.100000.","journal-title":"Forum Dermatol"},{"key":"2377_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/2050313x231160926","author":"LM Gresham","year":"2023","unstructured":"Gresham LM, Kirchhof MG. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report. SAGE Open Med Case Rep. 2023. https:\/\/doi.org\/10.1177\/2050313x231160926.","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"2377_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000489661","volume":"10","author":"K Thomsen","year":"2018","unstructured":"Thomsen K, Diernaes J, \u00d8llegaard TH, Spaun E, Vestergaard C. Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports. Case Rep Dermatol. 2018;10(2):154\u20137. https:\/\/doi.org\/10.1159\/000489661.","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"2377_CR42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Disc. 2012;11(8):633\u201352. https:\/\/doi.org\/10.1038\/nrd3800.","journal-title":"Nat Rev Drug Disc"},{"issue":"5","key":"2377_CR43","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1172\/JCI134983","volume":"130","author":"SS Iyer","year":"2020","unstructured":"Iyer SS, Cheng G, Yang X. Targeting IL-1 signaling pathways for the treatment of autoinflammatory diseases. J Clin Investig. 2020;130(5):2032\u201343. https:\/\/doi.org\/10.1172\/JCI134983.","journal-title":"J Clin Investig"},{"key":"2377_CR44","unstructured":"Novartis Pharmaceuticals. (2020). CANOPY-A: A phase III study of adjuvant canakinumab in non-small cell lung cancer (NSCLC). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03447769"},{"issue":"16","key":"2377_CR45","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1200\/JCO.2021.39.15_suppl.9005","volume":"40","author":"T Powles","year":"2022","unstructured":"Powles T, Eder JP, Hersey P, et al. CANOPY-1: a randomized phase III trial of canakinumab with pembrolizumab for advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2022;40(16):4515\u201324. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9005.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2377_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581\u2013611. https:\/\/doi.org\/10.1210\/er.2003-0027.","journal-title":"Endocr Rev"},{"issue":"4","key":"2377_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ccr.2013.09.022","volume":"24","author":"D Fukumura","year":"2006","unstructured":"Fukumura D, Kloepper JE, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using anti-VEGF therapy: strategies for combining anti-VEGF and immune checkpoint blockade. Cancer Cell. 2006;24(4):356\u201369. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.022.","journal-title":"Cancer Cell"},{"issue":"1","key":"2377_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.2004.06.082","volume":"22","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Van Cutsem E. Bevacizumab monotherapy in patients with metastatic colorectal cancer: a randomized, double-blind study. J Clin Oncol. 2004;22(1):38\u201343. https:\/\/doi.org\/10.1200\/JCO.2004.06.082.","journal-title":"J Clin Oncol"},{"key":"2377_CR49","doi-asserted-by":"publisher","unstructured":"Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor MJ; French Network of the Pharmacovigilance Centers.\nBevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol.\n2012;68(7):1103\u20131107. https:\/\/doi.org\/10.1007\/s00228-012-1232-7.","DOI":"10.1007\/s00228-012-1232-7"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02377-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:04:46Z","timestamp":1751360686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02377-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2377"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02377-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Waived by the IRB upon reviewing the manuscript (check IRB statement for more details on the ethical principles to which the IRB is compliant).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to particiapte"}},{"value":"Informed consent to participate and publish Fig.\u00a0 was obtained from the patient\u2019s next of kin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1195"}}